

Emerging Problems in Infectious Diseases

Zika virus infection, associated microcephaly, and low yellow fever vaccination coverage in Brazil: is there any causal link?

Luciano Pamplona de Góes Cavalcanti¹, Pedro Luiz Tauil⁵, Carlos Henrique Alencar¹, Wanderson Oliveira², Mauro Martins Teixeira³, Jorg Heukelbach^{1,4}

¹ Department of Community Health, School of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil ² Coordenação Geral de Vigilância e Resposta às Emergências em Saúde Pública do Ministério da Saúde do Brasil, Brasília, Brazil

³ Department of Biochemistry and Immunology, Biological Science Institute, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

⁴ Anton Breinl Centre for Public Health and College of Public Health, Medical and Veterinary Sciences, Division of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia ⁵ Faculty of Medicine, University of Brasília (UnB), Distrito Federal, DF, Brazil

Abstract

Introduction: Since the end of 2014, Zika virus (ZIKV) infection has been rapidly spreading in Brazil.

Methodology: To analyze the possible association of yellow fever vaccine with a protective effect against ZIKV-related microcephaly, the following spatial analyses were performed, using Brazilian municipalities as units: i) yellow fever vaccination coverage in Brazilian municipalities in individuals aged 15-49; ii) reported cases of microcephaly by municipality; and iii) confirmed cases of microcephaly related to ZIKV, by municipality. SaTScan software was used to identify clusters of municipalities for high risk of microcephaly.

Results: There were seven significant high risk clusters of confirmed microcephaly cases, with four of them located in the Northeast where yellow fever vaccination rates were the lowest. The clusters harbored only 2.9% of the total population of Brazil, but 15.2% of confirmed cases of microcephaly.

Conclusion: We hypothesize that pregnant women in regions with high yellow fever vaccination coverage may pose their offspring to lower risk for development of microcephaly. There is an urgent need for systematic studies to confirm the possible link between low yellow fever vaccination coverage, Zika virus infection and microcephaly.

Key words: Zika; Brazil; epidemiology.

J Infect Dev Ctries 2016; 10(6):563-566. doi:10.3855/jidc.8575

(Received 19 April 2016 - Accepted 09 June 2016)

Copyright © 2016 de Góes Cavalcanti *et al.* This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Since the end of 2014, Zika virus (ZIKV) infection has been rapidly spreading in Brazil, especially in the Northeast region of the country [1-4]. In June 2015, the Brazilian Ministry of Health (MoH) identified the first cases of neurological syndromes in patients with a history of exanthematic disease in endemic regions for arboviruses (ZIKV, DENV and Chikungunya virus) [5,6], and since September 2015 the number of notified cases of microcephaly has increased steadily [2]. As a consequence, MoH instructed the Federal States to report all cases of neurological syndromes and microcephaly [7]. By March 2016, a total of 6,381 suspected microcephaly cases were reported, and 854 confirmed; many of them occurred in infants born to women living in areas of ZIKV transmission. Transmission of ZIKV was confirmed in 22 of Brazil's 26 states including the Federal District.

ZIKV and yellow fever virus, in its urban transmission cycle, both share the same mosquito vector, *Aedes* mosquitoes. Yellow fever is an acute vector-borne short term viral disease. Despite the availability of an effective vaccine, there is still active transmission in many countries [8]. In Brazil, autochthonous cases of sylvatic yellow fever regularly occur in small clusters, transmitted by other mosquito species. In 2015, 7 autochthonous cases of yellow fever were reported [9]. Consequently, yellow fever vaccination is recommended for residents and for travelers directed to 18 of the 27 Federal States [10]. In the 9 remaining States, mostly located on the coastline along the Atlantic Ocean, transmission risk is considered very low to negligible, and vaccination of the general population is not recommended [11]. However, there is no consensus on expanding vaccination to the entire country [12].

Considering the close relation of other arboviruses with ZIKV, such as the yellow fever virus, it might be speculated that yellow fever vaccine to some extent may provide a protective effect against severe disease and sequelae caused by ZIKV infection, such as microcephaly.


Methods

Brazil is a country of continental dimensions, with a population of approximately 205 million inhabitants and 5,570 municipalities, with major parts of its territory considered as risk areas for yellow fever transmission.

Three different descriptive spatial analyses were performed, using the Brazilian municipalities as units of analysis: 1. yellow fever vaccination coverage in Brazilian municipalities in individuals aged 15-49 years; 2. reported cases of microcephaly by municipality; and 3. confirmed cases of microcephaly related to ZIKV, by municipality.

Spatial scan statistic analysis was performed, using SaTScan software package version 9.4.2 (Harvard Medical School, Boston, USA), to identify significant clusters of Brazilian municipalities for high risk of

Figure 1. (A) Yellow fever vaccination coverage in individuals aged 15-49 in Brazil; (B) reported cases of microcephaly between October 2015 and March 2016; (C) confirmed cases of microcephaly between October 2015 and March 2016; (D) clusters of confirmed cases of microcephaly associated with ZIKV; arrows indicate location of clusters. Observation units are the 5,570 municipalities of Brazil.



microcephaly. SaTScan uses a flexible geographic scanning window and includes different sets of neighboring areas. These clusters were identified using pure spatial analysis with a radius assuming 50% of the population at risk. Vaccination coverage data by municipality are freely available and were obtained from the Informatics Department of the Unified Health System - DATASUS (http://tabnet.datasus.gov.br). Notified and confirmed cases of microcephaly were provided by the Brazilian MoH.

Results

Data showed that in the Northeast of the country the region most heavily affected by Zika-related microcephaly - yellow fever vaccination coverage was the lowest (Figure 1A-C). We identified seven significant clusters at high risk for confirmed microcephaly cases, consisting of three or more municipalities (Figure 1D). Four out of these clusters were located in the Northeast of the country. The most extensive cluster consisted of 176 municipalities in Pernambuco (PE), Paraíba (PB) and Rio Grande do Norte (RN) states (Figure 1D), followed by another major cluster consisting of 110 municipalities in Bahia State (BA). There was also another isolated small cluster in Bahia State. An additional cluster in the northeast of the country includes Rio Grande do Norte (RN) and Paraíba (PB) States (59 municipalities). The remaining three clusters were smaller and located in other areas of the country, namely in Minas Gerais (MG) and São Paulo (SP) States. All clusters harbored only 2.9% of the total population of Brazil, but 15.2% of confirmed cases of microcephaly (p < 0.001). During the last 15 years, all 333 yellow fever cases occurred in areas where yellow fever vaccination is recommended.

Conclusion

Our analysis indicates that pregnant women in regions with high yellow fever vaccination coverage may pose their offspring to lower risk to develop microcephaly.

In fact, vaccination against Japanese encephalitis, dengue fever and yellow fever may produce crossreactive antibodies. Antibody cross-reactivity is known to occur between different flavivírus infections, such as yellow fever, Japanese encephalitis, and dengue fever [13,14], and in a historical study, a volunteer infected with ZIKV virus produced antibodies against both yellow fever virus and ZIKV [15].

We are aware that this is a small descriptive study, and that our ecological data are prone to confounders and bias (such as environmental factors that may influence the spread of Zika virus in yellow feverendemic areas). Therefore, no causal relationship can be established, and we emphasize an urgent need for systematic studies to confirm the possible link between low yellow fever vaccine coverage and microcephaly. Our data also suggest that a vaccine based on the existing yellow fever vaccine should be considered. Additional systematic studies are needed, such as a cohort study investigating yellow fever antibody titres in populations at risk. Adequately designed laboratorybased investigations and studies on animals need to be performed to investigate the possible protective effect of yellow fever vaccination against subsequent infection with Zika virus, and thus microcephaly.

References

- Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, Sall AA, Musso D (2014) Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis. 2014 20:1085-1086. doi: 10.3201/eid2006.140138 PubMed PMID: 24856001. Pubmed Central PMCID: PMC4036769.
- Heukelbach J, Alencar CH, Kelvin AA, De Oliveira WK, Pamplona de Goes Cavalcanti L (2016) Zika virus outbreak in Brazil. J Infect Dev Ctries. 10:116-120. PubMed PMID: 26927450.
- Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, do Carmo GM, Henriques CM, Coelho GE, Araújo de França GV (2016) Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika Virus transmission during the first trimester of pregnancy -Brazil, 2015. MMWR Morb Mortal Wkly Rep. doi: 10.15585/mmwr.mm6509e2. 65:242-247. PubMed PMID: 26963593.
- Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K (2015) First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz. 110:569-572. PubMed PMID: 26061233. Pubmed Central PMCID: PMC4501423.
- Ventura CV, Maia M, Bravo-Filho V, Gois AL, Belfort R, Jr (2016) Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet. 387:228. PubMed PMID: 26775125.
- Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM (2016) Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? Ultrasound Obstet Gynecol. 47:6-7. PubMed PMID: 26731034.
- Brasil. Protocolo de vigilância e resposta à ocorrência de microcefalia. Brasilia: Ministério da Saúde - Secretaria de Vigilância em Saúde; 2015 December 9, 2015. 55 p.
- 8. Chan M (2016) Yellow fever: the resurgence of a forgotten disease. Lancet. doi: 10.1016/S0140-6736(16)30620-1. [Epub ahead of print]
- Brasil. Ministério da Saúde. Ministério da saúde divulga boletim epidemiológico. 2016. Available from: http://portalsaude.gov.br/index.php/cidadao/principal/a gencia-saude/20805-ministerio-da-saudedivulga-boletimepidemiologico. Accessed 01 March 2016.
- Brasil. Nota informativa nº 143/CGPNI/DEVIT/SVS/MS 2014 [cited 2014 18 de Dezembro de 2014]. Available from:

http://sbmt.org.br/portal/wp-content/uploads/2015/02/Nota-Informativa-143-2014-Febre-Amarela.pdf

- Brasil. Secretaria de Vigilância em Saúde. Departamento de Vigilância em Saúde. Manual de vigilância de epizootias de primatas não humanos. Brasília: Ministério da Saúde; 2005.
- Cavalcante KRLJ, Tauil PL (2016) Epidemiological characteristics of yellow fever in Brazil, 2000-2012. Epidemiologia e Serviços de Saúde. 25:11-20.
- Mansfield KL, Horton DL, Johnson N, Li L, Barrett AD, Smith DJ, Galbraith SE, Solomon T, Fooks AR (2011) Flavivirusinduced antibody cross-reactivity. J Gen Virol. 92:2821-2829. doi: 10.1099/vir.0.031641-0
- Al-Qahtani A, Nazir N, Al-anazi M, Rubino S, Al-ahdal M (2016) Zika virus: a new pandemic threat. J Infect Dev Ctries. 10:201-207. doi:10.3855/jidc.8350

15. Bearcroft WG (1956) Zika virus infection experimentally induced in a human volunteer. Trans R Soc Trop Med Hyg. 50:442-8. PubMed PMID: 13380987.

Corresponding author

Luciano Pamplona de Góes Cavalcanti. Department of Community Health, School of Medicine, Federal University of Ceará, Rua Professor Costa Mendes 1608, 5. andar, Fortaleza CE 60430-140, Brazil. Phone: +55 85 3366.8045 Email: pamplona.luciano@gmail.com

Conflict of interests: No conflict of interests is declared.